AI isn’t close to curing cancer. This startup says it knows what it will take.

Vivodyne’s HIVE robotic labs grow 20 human tissue types, autonomously dosing and monitoring them to generate causal biological data. The company reports 94% accuracy in liver toxicity predictions, 96% airway tissue behavior match, and 100% concordance in bone-marrow tests for 20 chemotherapy drugs. With under $80 million in funding, Vivodyne operates a large “human data center” near San Francisco, doubling U.S. animal trial throughput to speed drug candidate validation before clinical trials.